This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).
To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin. The Summit found that cannabis does not enhance athletic performance.
Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D. Christine Lawson. She acknowledged that “FDA is considering the possibility of new legal pathways for CBD products.”.
Vancouver, British Columbia – TheNewswire – January 10, 2022 – Lexston Life Sciences Corp. Both parties hold licenses in their respective jurisdictions for scientific research on cannabis and are applicants for psychedelic research licenses with the US DEA and Health Canada. Egret”) and Panacea Plant Sciences Inc.
What about the DEA? DEA lawsuits or answer the question of whether DEA asserts that delta-8 is synthetically derived, although it does lend credibility to the HIA’s arguments regarding the legality of delta-8 based on the plain language of the 2018 Farm Bill. 4 th 682, 686 (9th Cir. View source.].
Apr 12, 2022, 07:00 ET. Transaction expected to close in June 2022 , following anticipated shareholder approval. The offer price represents a premium of 51% to Novamind’s 20-day volume-weighted average price (“VWAP”) on the Canadian Securities Exchange (the “CSE”) as of April 8, 2022.
Currently Hemp Acres has 3000 acres under contract for 2021 production and anticipates contracting 10,000 acres in 2022. In the past, the organization’s approach primarily involved educating members on relevant hemp issues during events that it hosted. Adding a 21+ age restriction on delta-8 products.
Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. state and federal law to U.S.
A representative of the Impact Forum told Marijuana Moment in an email that the event “is private and we do not issue transcripts, audio or video.”. “No — Cannabis & Tech Today (@cannatechtoday) February 24, 2022. He reportedly said definitively at the event that “CBD works.”.
Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. aeidinger) May 9, 2022. DeaOutoftheway @RTTpsilocybin pic.twitter.com/1NJWt2cJWn.
billion made in two years, just two years from January 2020 to January 2022. We will be having an event in March 31, I believe, where we’ll be kind of doing our big coming out party and talking about fundraising for our members and our students. Let’s be clear, it’s not like nothing’s up.
The 9th Circuit may hear a challenge to the DEA’s marijuana scheduling. Commercial sales will begin in 2022. Further bulletins as events warrant! They challenge the Drug Enforcement Administration’s (DEA) classification of cannabis as a Schedule I drug. The DEA’s brief in response is due late next month.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content